Sugi Predict

Sugi Predict / Compounds / SCHEMBL1850336

SCHEMBL1850336

SCHEMBL1850336

CN(C)C[N]c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.46
▸ MAOB P27338 2/20 0.46
▸ CYP2C19 P33261 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ ADRA2A P08913 3/20 0.42
▸ ADRA2B P18089 3/20 0.42
▸ ADRA2C P18825 3/20 0.42
▸ PLAU P00749 1/20 0.42
▸ NOS3 P29474 2/20 0.41
▸ NOS1 P29475 2/20 0.41
▸ NOS2 P35228 2/20 0.41
▸ KCNH2 Q12809 4/20 0.40
▸ CHRM2 P08172 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SCN1A P35498 1/20 0.38
▸ SCN2A Q99250 1/20 0.38
▸ SCN3A Q9NY46 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235378 0.81 NOS3 (0.42) MAOAMAOBCYP2D6ADRA2AADRA2B
SCHEMBL1629938 0.77 — —
SCHEMBL7713660 0.73 NOS3 (0.46) MAOAMAOBCYP2C19CYP2D6ADRA2A
SCHEMBL1853723 0.72 MAOA (0.50) MAOAMAOBCYP2C19TSHRCYP2D6
SCHEMBL1849181 0.72 HRH3 (0.44) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL3499052 0.72 MAOA (0.50) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL3499053 0.72 MAOA (0.50) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL6603664 0.71 NOS3 (0.44) MAOAMAOBCYP2C19CYP2D6ADRA2A
SCHEMBL20658871 0.69 MAOA (0.56) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL20658872 0.69 MAOA (0.56) MAOAMAOBADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA MAOA 3294/4885MAOB 2730/4885CYP2C19 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.